Deutsche Bank has upgraded Kingfisher PLC from 'sell' to 'hold' and increased its price target to 300p from 260p. The upgrade follows better-than-expected earnings and a sequential improvement in industry data, despite ongoing UK cost pressures and a soft European consumer outlook. Deutsche Bank raised its full-year pre-tax profit forecast to £605 million, above market consensus and Kingfisher's own guidance midpoint. The bank's more neutral stance reflects confidence in Kingfisher's performance amid macroeconomic challenges.
Kingfisher's recent upgrade by Deutsche Bank is presented here alongside Pluang's Consumer Cyclical sector data for context. For readers following this sector, as of Sep 17, 2026 23:41 WIB, 70 out of 105 US stocks rose. Notably, Best Buy Co Inc increased by 3.90% to USD 95.06 with a typical hold time of 64 days and a Pluang order activity skewed 100% to sell, contrasting with Burlington Stores Inc and General Motors Company, which both rose around 3.8% and 3.6% respectively, with 100% buy order activity and shorter to longer hold times.
In Q3 2026, websites on Cloudflare's network blocked 13.47% of AI crawler requests, more than double the 5.98% blocked a year earlier. This rise in access denial affects how brands appear in AI-generated answers from platforms like ChatGPT, Gemini, a...
JPMorgan Asset Management (Canada) announced the final cash distributions for September 2026 for three of its ETFs traded on the Toronto Stock Exchange. Unitholders of record on October 19, 2026, will receive payments on October 23, 2026. The ETFs an...
Stillwater Critical Minerals Corp. has upgraded to the OTCQX Best Market from the OTCQB Venture Market, beginning trading under the symbol "PGEZF." This move enhances the company's visibility, liquidity, and accessibility to U.S. investors as it adva...
WasabiCard, a stablecoin-based global payment provider, engaged in key partnership discussions at TOKEN2049 Singapore 2026, focusing on white-label card issuing, global payouts, and embedded payments. The company highlighted growing demand in APAC fo...
The global next generation antibody therapeutics market is projected to increase from $5.45 billion in 2026 to $5.76 billion by 2035, growing at a CAGR of 1%. Growth is fueled by advances in biotechnology, rising demand for targeted therapies, and in...
